LTS and AWAKN LIFE SCIENCES enter into global licensing agreement for proprietary sublingual (S)-ketamine formulation
The agreement is for a proprietary (S)-ketamine formulation, administered sub-lingually via an oral thin film (OTF) and Awakn will have global exclusivity of its use for Treatment of Addiction, Anxiety Disorders, and Eating Disorders.









